Gyre Therapeutics (GYRE) Return on Sales (2010 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales rose to 0.0% in Q1 2026 per GYRE's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Sales peaked at 0.04% in Q3 2022 and troughed at 0.18% in Q1 2022.
• A 5-year average of 0.01% and a median of 0.0% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales declined 3 bps in 2022, then grew 18 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then plunged by 1253 bps to 0.04% in 2023, then jumped by 79 bps to 0.01% in 2024, then rose by 27 bps to 0.01% in 2025, then grew by 22 bps to 0.0% in 2026.
• Business Quant data shows GYRE's Return on Sales at 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.